{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:59:28Z","timestamp":1789009168932,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background and purpose:<\/jats:bold> poly-ADP ribose polymerase (PARP) inhibitors show impressive efficacy in a range of tumors. However, concerns about rare and fatal adverse events, including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) have arisen. The aim of this study was to excavate and evaluate the risk of PARP inhibitors causing MDS and AML based on real-world data from two international pharmacovigilance databases.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We analyzed adverse event (AE) reports of four PARP inhibitors (olaparib, niraparib, rucaparib and talazoparib) associated with MDS and AML from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and EudraVigilance (EV) databases between 1 October 2014, and 30 September 2021, including demographic characteristics, fatality and times to onset. Three different data mining algorithms were used to detect the signals of PARP inhibitors associated with MDS and AML.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In total, 16,710 and 11,937 PARP inhibitor AE reports were found in the FAERS and EV databases, of which 332 and 349 were associated with MDS and AML, respectively. The median latencies of MDS and AML associated with PARP inhibitors were 211 [interquartile range (IQR) 93.5\u2013491.25] days and 355 (IQR 72.00\u2013483.50) days, respectively. The average fatality rates of MDS and AML caused by the four PARP inhibitors were 39.23 and 45.39%, respectively, in the FAERS database, while those in the EV database were 32.32 and 34.94%, respectively. Based on the criteria used for the three algorithms, a significant disproportionate association was found between PARP inhibitors as a drug class and MDS\/AML. Notably, the risk of MDS was much higher than that of AML. Olaparib appeared to have a stronger association with MDS and AML than did other PARP inhibitors.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> In the real world, PARP inhibitors increase the risk of MDS and AML, which can result in high mortality and tend to occur during long-term use. Our findings provide objective evidence for the postmarketing safety of PARP inhibitors.<\/jats:p>","DOI":"10.3389\/fphar.2022.912256","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T04:57:01Z","timestamp":1655269021000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Myelodysplastic Syndrome\/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data"],"prefix":"10.3389","volume":"13","author":[{"given":"Quanfeng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peishu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.nucmedbio.2016.08.007","article-title":"Iodinated Benzimidazole PARP Radiotracer for Evaluating PARP1\/2 Expression In Vitro and In Vivo","volume":"43","author":"Anderson","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","article-title":"Bayesian Confidence Propagation Neural Network","volume":"30","author":"Bate","year":"2007","journal-title":"Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","article-title":"Pharmacovigilance-based Drug Repurposing: The Search for Inverse Signals via OpenVigil Identifies Putative Drugs against Viral Respiratory Infections","volume":"87","author":"B\u00f6hm","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1200\/JCO.2020.38.15_suppl.1513","article-title":"The Impact of Poly ADP Ribose Polymerase (PARP) Inhibitors on Clonal Hematopoiesis","volume":"38","author":"Bolton","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib Maintenance Treatment for Recurrent Ovarian Carcinoma after Response to Platinum Therapy (ARIEL3): a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00412-014-0482-9","article-title":"DNA Damage Accumulation and Repair Defects in Acute Myeloid Leukemia: Implications for Pathogenesis, Disease Progression, and Chemotherapy Resistance","volume":"123","author":"Esposito","year":"2014","journal-title":"Chromosoma"},{"key":"B8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2407-7-152","article-title":"The BRCA1\/2 Pathway Prevents Hematologic Cancers in Addition to Breast and Ovarian Cancers","volume":"7","author":"Friedenson","year":"2007","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s12885-020-06903-4","article-title":"Different Regulation of PARP1, PARP2, PARP3 and TRPM2 Genes Expression in Acute Myeloid Leukemia Cells","volume":"20","author":"Gil-Kulik","year":"2020","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/1541-7786.Mcr-18-0138","article-title":"PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow","volume":"17","author":"Hopkins","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa191144010.1056\/NEJMoa2022485","article-title":"Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.1016\/S1470-2045(18)30786-1","article-title":"Exploring and Comparing Adverse Events between PARP Inhibitors","volume":"20","author":"LaFargue","year":"2019","journal-title":"Lancet Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP Inhibitors: Synthetic Lethality in the Clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"100033","DOI":"10.1016\/j.esmoop.2020.100033","article-title":"Poly(ADP-ribose) Polymerase Inhibitor-Associated Myelodysplastic Syndrome\/acute Myeloid Leukemia: a Pharmacovigilance Analysis of the FAERS Database","volume":"6","author":"Ma","year":"2021","journal-title":"ESMO Open"},{"key":"B18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejca.2021.08.016","article-title":"Secondary Haematologic Malignancies in Women with Ovarian Cancer Receiving Poly-ADP Ribose Polymerase Inhibitor Therapy","volume":"157","author":"Matsuo","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1002\/cncr.28641","article-title":"Underestimation of Myelodysplastic Syndrome Incidence by Cancer Registries: Results from a Population-Based Data Linkage Study","volume":"120","author":"McQuilten","year":"2014","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e13331","DOI":"10.1111\/ijcp.13331","article-title":"Assessing Fluoroquinolone-Associated Aortic Aneurysm and Dissection: Data Mining of the Public Version of the FDA Adverse Event Reporting System","volume":"73","author":"Meng","year":"2019","journal-title":"Int. J. Clin. Pract."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic Syndrome and Acute Myeloid Leukaemia in Patients Treated with PARP Inhibitors: a Safety Meta-Analysis of Randomised Controlled Trials and a Retrospective Study of the WHO Pharmacovigilance Database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","article-title":"Association of Chemotherapy for Solid Tumors with Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era","volume":"5","author":"Morton","year":"2019","journal-title":"JAMA Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.ygyno.2021.03.011","article-title":"Incidence of Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients Receiving Poly-ADP Ribose Polymerase Inhibitors for the Treatment of Solid Tumors: A Meta-Analysis of Randomized Trials","volume":"161","author":"Nitecki","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/pds.3998","article-title":"Geographical Variation in Reporting Interstitial Lung Disease as an Adverse Drug Reaction: Findings from an European Medicines Agency Analysis of Reports in EudraVigilance","volume":"25","author":"Pinheiro","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib Tablets as Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1\/2 Mutation (SOLO2\/ENGOT-Ov21): a Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib Tablets as Maintenance Therapy in Patients with Platinum-Sensitive, Relapsed Ovarian Cancer and a BRCA1\/2 Mutation (SOLO2\/ENGOT-Ov21): a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib Plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The Reporting Odds Ratio and its Advantages over the Proportional Reporting Ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1093\/eurheartj\/ehab362","article-title":"Anticancer Drug-Induced Life-Threatening Ventricular Arrhythmias: a World Health Organization Pharmacovigilance Study","volume":"42","author":"Salem","year":"2021","journal-title":"Eur. Heart J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ygyno.2018.09.003","article-title":"Incidence of Secondary Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Ovarian or Breast Cancer in a Real-World Setting in the United States","volume":"151","author":"Shenolikar","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer Statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"key":"B35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.critrevonc.2018.08.011","article-title":"The Era of PARP Inhibitors in Ovarian Cancer: \"Class Action\" or Not? A Systematic Review and Meta-Analysis","volume":"131","author":"Staropoli","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1021\/acs.jmedchem.6b00990","article-title":"Structural Basis for Potency and Promiscuity in Poly(ADP-Ribose) Polymerase (PARP) and Tankyrase Inhibitors","volume":"60","author":"Thorsell","year":"2017","journal-title":"J. Med. Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."}],"updated-by":[{"DOI":"10.3389\/fphar.2022.990048","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.912256\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T16:32:49Z","timestamp":1660321969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.912256\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":38,"alternative-id":["10.3389\/fphar.2022.912256"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.912256","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fphar.2022.990048","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]},"article-number":"912256"}}